According to the recent research report titled ‘Global Generic Injectables Market (2022 Edition) - Analysis By Molecule Type, (Small, Large), Therapeutic Area, Container Type, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2022-2027)’ available with MarketStudyReport, global generic injectables market accounted for USD 134 billion in 2021 and is estimated to generate lucrative returns by the year 2027.

Rising usage of generic injectable medicines, increasing concerns over the expiration of branded drug patents, growing geriatric population, and increasing prevalence of life-threatening diseases are some of the major factors fueling global generic injectables market growth.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4814124/  

The other factors fueling the overall market size are the affordability of generic injectables and their extensive usage in treating diseases like diabetes, cardiovascular diseases, and cancer. The positive development of the market is, however, constrained by issues with the supply chain and requirement of crucial inspection of prefilled injection.

The global generic injectables market is segmented based on container type, molecular type, therapeutic value, and geographical analysis. The molecular type is further split into small molecules and large molecule segments. Meanwhile, the therapeutic value segment of this marketplace is bifurcated into anti-infectives, cardiovascular diseases, diabetes, oncology, and others.

In terms of geographical analysis, the industry is divided into North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa. Among these, Asia Pacific is estimated to emerge as the fastest-growing market during the study timeline primarily due to the rise in demand for generic injectables from Indian companies.

On the other hand, North America has been predominantly strong in terms of market share and is expected to hold its position in the subsequent years due to rising usage of generic injectable medicines and increasing concerns over the expiration of branded drug patents.

The leading companies operating in worldwide generic injectables market space are Fresenius SE & Co. KGaA, Pfizer Inc., Gland Pharma Ltd., Teva Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals plc, Novartis AG, Sanofi S.A., Baxter International Inc., and Nichi-iko Pharmaceutical Co. Ltd.